#Germany #healthcare #Berlin #AMBOSS #MedicalEducation

AMBOSS Secures €240M Financing for Expansion

In a significant move for healthcare education and clinical decision-making, AMBOSS, the prominent educational resource in Germany and the United States, has secured a financing round totaling €240 million. This investment will enable the company to expand into new international markets and broaden its offerings to include not only physicians but also nurses and other healthcare professionals.

A New Era of Growth and Investment

Recently transforming into a European stock corporation (SE), AMBOSS has attracted several long-term investors such as KIRKBI, MG Investments, and Lightrock, alongside existing shareholders. Benedikt Hochkirchen, Co-Founder and Co-CEO of AMBOSS, stated, "We choose investors who are committed to our long-term vision and very flexible in the investment duration." These funds are earmarked for further technological advancements and market segment expansions, focusing on strategic acquisitions, such as Novaheal, a nursing field startup, and NEJM Knowledge+, a board exam preparation tool for U.S. residents. This financial boost significantly enhances AMBOSS's capital access previous to a potential IPO.

Empowering Healthcare Professionals

AMBOSS is at the forefront of digitizing healthcare education by ensuring that medical practitioners are the focal point in the development of tools designed to enhance care delivery. Doctors globally trust AMBOSS to deliver the latest medical content complemented by state-of-the-art technology. "Technology will not replace healthcare professionals, but those who embrace it will lead the way," commented Dr. Madjid Salimi, Co-Founder and Co-CEO.

With over 1 million users across 180 countries, AMBOSS has become integral to clinical decision-making. Notably, it supports one in every two inpatient treatments in Germany, showing the profound trust placed in its resources. In the United States, it has gained traction among medical students who not only use AMBOSS for exam preparations but also achieve better scores compared to other resources. Approximately 25% of first-year U.S. residents rely on AMBOSS for superior patient care.

The Trustworthiness of AMBOSS

The foundation of AMBOSS's success lies in its collaborative approach, where seasoned medical professionals work hand-in-hand with technology experts. AMBOSS delivers precise and actionable recommendations based on the most current diagnostic and treatment guidelines. As a digital co-pilot in everyday clinical practice, it significantly aids healthcare providers in saving time and minimizing errors. The responsible use of AI technologies has been a hallmark of the AMBOSS experience, garnering the respect of educators and healthcare professionals worldwide. The company remains committed to leading through comprehensive outcome validation and a value-first mindset.

Investors like Peter Bason, Head of Private Capital at KIRKBI, have closely followed AMBOSS’s growth trajectory, highlighting its focus on innovation and the importance of its platform for both students and healthcare professionals. He stated, "We are excited to collaborate with seasoned technology and growth investors to support AMBOSS's vision to empower future generations of healthcare professionals globally."

A Visionary Foundation

Established in 2012 by a group of physicians, AMBOSS is a revolutionary platform that has transformed how medical knowledge is acquired and applied in practical settings. The company prioritizes high-quality content, cutting-edge AI technology, and a user-centric design, employing over 500 professionals from over 50 countries, including scientists and over 150 physicians. AMBOSS continues to serve as a trusted partner for medical knowledge, with more than 1 million professionals utilizing its services worldwide. For more insights into their groundbreaking work, visit www.amboss.com.